Many Great Treatments Available for MCL But Questions About Sequencing Remain, Expert Says


In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.

Survival has extended significantly over the years for patients with mantle cell lymphoma as treatments have evolved, but questions around sequencing still remain, according to Hun Ju Lee, MD.

In a conversation with CancerNetwork® during the 2022 American Society of Hematology (ASH) Annual Meeting, Lee, an assistant professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, also highlighted the importance of shared decision making when treating this patient population.


Historically, when I was starting off, median overall survival for mantle cell lymphoma was three years. Now, it's [somewhere between] 25 to 30 years given the treatment options. There are so many great treatment options. [As to] how we sequence them is still a key question. Which should come first, and which should come after that?

That is really going to incorporate not just the physicians and the oncologist, but you'll need the patient’s input as to what [adverse] effects they are willing to accept. I recognize the risk is taken by the patient, so they really need to be informed of the of the subtleties of the risk that is involved in selecting treatment options.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.